A strain of Bacillus saffron and its application

Through Bacillus safferi SK14 and its metabolite ephedrine, the complex problem of MRSA infection treatment was solved, demonstrated significant anti-inflammatory and antioxidant effects, and provided a safe and effective alternative treatment plan, reducing the MRSA-induced treatment Acute lung injury and inflammation.

CN118497092BActive Publication Date: 2024-11-26JILIN AGRICULTURAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410980059.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-26
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection is complex, existing antibiotic resistance increases, and there is a lack of effective alternative treatment strategies.

Method used

Bacillus safensis SK14 and its metabolite ephedrine have shown significant anti-inflammatory and antioxidant abilities for acute lung injury caused by MRSA, and by inhibiting M1 macrophage polarization and promoting M2 Macrophages polarize, reducing inflammation and oxidative stress.

Benefits of technology

Bacillus safferium SK14 and its fermented ephedrine significantly reduced the inflammatory response stimulated by MRSA, improved the survival rate of mice, reduced lung inflammation and MRSA colonization, enhanced antioxidant capacity, and provided a safe and effective Alternative treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118497092B_ABST
    Figure CN118497092B_ABST
Patent Text Reader

Abstract

The present application provides a strain of Bacillus sabovici and its application, belonging to the field of microorganisms. The Bacillus sabovici described in the present application is named Bacillus sabovici ( Bacillus safensis )SK14, which was deposited in the China Center for Type Culture Collection at Wuhan University, Wuhan, China on May 27, 2024, with the deposit number CCTCC NO:M 20241071. The strain has antibacterial, anti-inflammatory and antioxidant capabilities, can protect cells from infection by methicillin-resistant Staphylococcus aureus, and has a protective effect on acute lung injury caused by methicillin-resistant Staphylococcus aureus. In addition, the strain can produce a small molecule metabolite aesculin, providing a safer and more effective source of aesculin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of microorganisms, and in particular to a strain of Bacillus saffron and its application. Background Art

[0002] Any discussion of the prior art throughout the specification should not be considered as an admission that such prior art is widely known or forms part of the common general knowledge in the field.

[0003] Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most representative drug-resistant bacteria in the world and an important cause of sepsis in clinical practice, which seriously affects global public health. Septic infections caused by MRSA are often accompanied by acute lung injury (ALI), hypoxemia, and acute respiratory distress syndrome (ARDS). MRSA is resistant to almost all β-lactam antibiotics and can acquire resistance to other drug classes, including vancomycin, linezolid, and daptomycin, which were once considered the last resort for treating severe MRSA infections. This situation complicates the treatment of MRSA infections. Given the increasing prevalence of multidrug-resistant MRSA strains and the slowdown in antibiotic development, new alternative treatment strategies are urgently needed to combat bacterial infections.

[0004] Probiotics refer to live microorganisms that are beneficial to the host's health when ingested in adequate amounts. They can produce antimicrobial substances, regulate the host's immune system, and directly interact with pathogens. Therefore, more and more research is focused on exploring the role of probiotics and their related antimicrobial metabolites in the prevention and treatment of Staphylococcus aureus infections. In vitro experiments by Shen et al. showed that 15 strains of Hansen yeast and Star yeast isolated from grape skin had a strong antagonistic effect on MRSA. Among them, S. bacillaris CC-PT4 exhibits antibacterial and biofilm inhibition effects through its small molecule metabolite 2-amino-1-phenylethanol (APE). Xiang et al. identified the bacteriocin XJS01 as a potential alternative antibiotic against multidrug-resistant (MDR) Staphylococcus aureus, showing superior antibacterial effects than mupirocin in in vitro and in vivo experiments. In addition, previous studies have shown that sodium butyrate associated with the Clostridiaceae family can enhance the gut-lung axis microbiota, promote the polarization of alveolar macrophages to the M2 phenotype, and effectively prevent MRSA-induced pneumonia. These findings suggest that microbial-derived metabolites have potential in combating MRSA infection. Summary of the invention

[0005] Therefore, the purpose of this application is to provide a strain of Bacillus sabovici and its application. The Bacillus sabovici described in this application is named Bacillus sabovici ( Bacillus safensis)SK14, which can metabolize to produce esculin, and its strain and its fermentation products showed a protective effect against acute lung injury caused by methicillin-resistant Staphylococcus aureus, displayed significant anti-inflammatory and antioxidant abilities, and were safe and non-toxic.

[0006] Specifically, the present application provides the following technical features, and a combination of one or more of the following technical features constitutes the technical solution of the present application.

[0007] In the first aspect of the present application, a strain of Bacillus sabogensis is provided, and its name is Bacillus sabogensis ( Bacillus safensis ) SK14, the strain has been deposited in the China Center for Type Culture Collection located in Wuhan University, Wuhan, China on May 27, 2024, with the deposit number being CCTCC NO: M 20241071. The Bacillus safovici described in this application ( Bacillus safensis ) SK14 is also referred to as BS SK14 in this application.

[0008] BS SK14 is safe and non-toxic. This application evaluates the safety of BS SK14. No obvious signs of toxicity or lethality were observed in any experimental animal group throughout the scientific analysis. In addition, during the two-week observation period, there was no significant deviation in the average body weight of animals in the BS SK14 group and the PBS group. In further serum biochemical analysis, there was no significant difference in the concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine (CK) or blood urea nitrogen (BUN) between the BSSK14 group and the PBS group. The levels of serum inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) or interleukin-1β (IL-1β) remained unchanged without significant changes, and no significant abnormalities were found in histopathological examinations of key organs (including heart, liver, lungs, kidneys or spleen).

[0009] BS SK14 exhibits a high anti-inflammatory potential. In the study of this application, it was found that BS SK14 could significantly reduce the NO production in MRSA-stimulated RAW 264.7 cells to less than 10%, but did not affect the NO level of normal macrophages not infected with MRSA.

[0010] BS SK14 has a protective effect on MRSA-induced acute lung injury in mice, especially live strains. In the study of this application, the survival rate of mice pretreated with live strain BS SK14 was significantly higher, and it could reduce the thickening of alveolar walls and the massive infiltration of inflammatory cells caused by MRSA infection, reduce the levels of proinflammatory cytokines such as IL-6, IL-1β and TNF-α, and reduce the level of malondialdehyde (MDA), and increase the levels of antioxidants superoxide dismutase (SOD), glutathione (GSH) and total antioxidant capacity (T-AOC).

[0011] The culture supernatant of BS SK14 showed significant bactericidal activity, significantly reduced the MRSA count in the lungs, and was able to reduce the levels of proinflammatory cytokines such as IL-6, IL-1β and TNF-α, as well as reduce the level of MDA and increase the levels of antioxidants (SOD, GSH and T-AOC).

[0012] The present application performed principal component analysis (PCA) on the culture supernatant of BS SK14, which can produce the metabolite aesculin. In the present application study, it was found that with the application of aesculin, the cell damage caused by MRSA was significantly reduced and dose-dependent. Further studies in the present application showed that BS SK14 protected RAW264.7 cells from MRSA infection through its small molecule metabolite aesculin. This protection may be due to aesculin inhibiting MRSA-induced M1 macrophage polarization and promoting M2 macrophage polarization, and also leading to other anti-inflammatory and antioxidant effects.

[0013] At the same time, the present application demonstrates the protective effect of esculin on ALI caused by MRSA, which is manifested in that esculin significantly improves the survival results of ALI model mice and prolongs the survival curve. Histopathological evaluation further confirms the therapeutic effect of esculin, which significantly reduces pulmonary congestion, interstitial edema, and alveolar wall thickness, resulting in a significant reduction in inflammatory cell infiltration, and has good anti-inflammatory ability, which can significantly reduce IL-6, IL-1β and TNF-α levels, reduce pulmonary edema, reduce inflammatory cell infiltration, and increase the clearance rate of bacteria and reduce MRSA colonization in the lungs. In addition, esculin can enhance antioxidant capacity, reduce MDA levels, and increase the levels of antioxidants (SOD, T-AOC and GSH), and esculin has been proven to have anti-inflammatory effects and tissue repair capabilities on ALI model mice, and can inhibit the polarization of mouse M1 macrophages caused by MRSA (reducing the expression level of M1 marker iNOS) and promote the polarization of M2 macrophages (increasing the expression level of M2 marker ARG1).

[0014] Furthermore, the present application demonstrates that esculin promotes macrophage M2 polarization through the Keap1 / Nrf2 / ARE and TLR2-MyD88-NFκB pathways, and that esculin can reduce the expression levels of TLR2, MyD88, and phosphorylated NF-κBp65 in the lung tissues of MRSA-induced ALI model mice, and can alleviate the oxidative stress caused by ALI.

[0015] In a second aspect of the present application, a fermentation product of BS SK14 is provided.

[0016] The fermented product contains aesculin, a metabolite of BS SK14.

[0017] In a third aspect of the present application, a composition is provided, comprising BS SK14 or a fermentation product thereof.

[0018] In a fourth aspect of the present application, provided is the use of BS SK14 or a fermentation product of BS SK14 or a composition comprising BS SK14 or a fermentation product thereof in the preparation of a medicament for preventing and / or treating acute lung injury caused by methicillin-resistant Staphylococcus aureus.

[0019] In the fifth aspect of the present application, provided is the use of BS SK14 or a fermentation product of BS SK14 or a composition comprising BS SK14 or a fermentation product thereof in the preparation of a drug for inhibiting the TLR2-MyD88-NFκB signaling pathway and / or a drug for activating the Nrf2 / ARE signaling pathway.

[0020] In a sixth aspect of the present application, provided is the use of BS SK14 or a fermentation product of BS SK14 or a composition comprising BS SK14 or a fermentation product thereof in the preparation of a medicament having anti-inflammatory and / or antioxidant effects.

[0021] In a seventh aspect of the present application, provided is the use of BS SK14 or a fermentation product of BS SK14 or a composition comprising BS SK14 or a fermentation product thereof in the preparation of an antibacterial drug or an anti-infective drug.

[0022] In the present application, the antibacterial agent includes anti-methicillin-resistant Staphylococcus aureus, which is characterized by reducing the number of methicillin-resistant Staphylococcus aureus. The anti-infection agent includes anti-methicillin-resistant Staphylococcus aureus caused infection.

[0023] In the eighth aspect of the present application, a method for producing aesculin is provided, characterized in that it comprises: culturing BSSK14 and obtaining aesculin from its fermentation broth.

[0024] The present application provides a safer and more effective source for producing aesculin.

[0025] Compared with the prior art, the advantages of the present application include: the present application provides a strain of Bacillus saffron ( Bacillus safensis )SK14 (BS SK14), BS SK14 is safe and non-toxic, and can significantly reduce NO production in MRSA-stimulated RAW264.7 cells to less than 10%, showing its high anti-inflammatory potential. BS SK14 has a protective effect on MRSA-induced acute lung injury in mice. BS SK14 protects RAW264.7 cells from MRSA infection through its small molecule metabolite aesculin. This protection may be through aesculin inhibiting MRSA-induced M1 macrophage polarization and promoting M2 macrophage polarization, and leading to other anti-inflammatory and antioxidant effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The drawings constituting part of the present application are used to provide a further understanding of the present application. The illustrative embodiments and descriptions of the present application are used to explain the present application and do not constitute an improper limitation on the present application. The implementation scheme of the present application is described in detail below in conjunction with the drawings, wherein:

[0027] Figure 1 The results of the screening and safety evaluation of anti-inflammatory probiotics in sauerkraut are shown, including: A: the screening process of probiotics in Northeast China Sauerkraut; B: the effect of probiotics on NO production in RAW 264.7 cells induced by MRSA; C: the effect of BS SK14 on TNF-α, IL-6 and IL-1β production in RAW 264.7 cells induced by MRSA; D: weight gain after 14 days of pretreatment with PBS and BS SK14; E: serum ALT level; F: AST level; G: CK level; H: LDH level; I: BUN level; J: serum TNF-α level; K: serum IL-6 level; L: serum IL-1β level; M: histological scores and representative H&E stained sections of the heart, liver, spleen, lung and kidney of mice pretreated with PBS and BS SK14 (magnification: ×200). Data in the figure are shown as mean ± SEM; n = 3-5.

[0028] Figure 2The figure shows the protective effect of live BS SK14 on MRSA-induced ALI in mice, where A: Experimental design of the ALI model and pretreatment with live BS SK14 or dead BS SK14; B: Representative H&E staining and histological observation images of the lungs of control and ALI mice; C: Kaplan-Meier survival curves of mice in each group; D: Histological Scores of the lungs; E: ELISA results of IL-1β and TNF-α cytokine expression in the lungs; F: Lung wet / dry weight ratio); G: protein concentration in bronchoalveolar lavage fluid (BALF); H: representative images of MRSA bacterial load in the lungs; I: quantitative results of MRSA bacterial load in the lungs; J: neutrophils in BALF; K: macrophages in BALF; L: MDA level in the lungs; M: SOD level in the lungs; N: GSH level in the lungs; O: T-AOC level in the lungs. Data are shown as mean ± SEM; n = 5-10.

[0029] Figure 3 The effects of BS SK14 culture supernatant (SUP BS SK14) on ALI mice are shown, where A: experimental design of ALI model and pretreatment with blank supernatant (Blank SUP) or live BS SK14 supernatant (SUP BS SK14); B: representative H&E staining and histological observation images of the lungs of control and ALI mice; C: Kaplan-Meier survival curves of mice in each group; D: histological scores of the lungs; E: ELISA results of IL-1β and TNF-α cytokine expression in the lungs; F: wet / dry weight ratio of the lungs; G: protein concentration in BALF; H: representative images of MRSA bacterial load in the lungs; I: quantitative results of MRSA bacterial load in the lungs; J: neutrophils in BALF; K: macrophages in BALF; L: MDA levels in the lungs; M: SOD levels in the lungs; N: GSH levels in the lungs; O: T-AOC levels in the lungs. Data in the figure are shown as mean ± SEM; n = 5-10.

[0030] Figure 4The figure shows that esculin in the culture supernatant of BS SK14 alleviates MRSA-induced inflammation and oxidative stress by regulating macrophage polarization of RAW 264.7 cells, wherein, A: Screening scheme of effective metabolites of BS SK14 against MRSA by LC-MS / MS analysis; B: PCA scatter plot of non-targeted metabolomics analysis from blank NB culture medium and SK14 supernatant; C: Molecular structure of esculin; D: Volcano plot of non-targeted metabolomics analysis (BS SK14 group vs blank NB group); E: Order of multiple change values ​​of different expressed metabolites; F: Evaluation of cytotoxicity of esculin by LDH assay, RAW264.7 cells were pretreated with specified concentrations (30-150 μM) for 24 h and then tested. In order to determine the protective effect of esculetin against MRSA infection, RAW264.7 cells were pretreated with specified concentrations (30-150 μM) for 24 h. μM) pretreatment for 1 hour, followed by co-stimulation with MRSA for 4 hours; G: Cell damage was assessed by LDH assay; H: Levels of IL-1β, IL-1β, and TNF-α were detected by western blot; I: Flow cytometry showed the cell surface expression of CD86 and CD206 in M1 and M2 populations; J: ELISA results showed the expression of TNF-α, IL-1β, and IL-6 cytokines in the cell supernatant (cells were pretreated with 120 μM Esculin for 1 hour, followed by co-stimulation with MRSA for 4 hours); K: MDA level in cell supernatant; L: T-AOC level in cell supernatant; M: SOD level in cell supernatant; N: GSH level in cell supernatant; In K to N, cells were pretreated with 120 μM Esculin for 1 hour, followed by co-stimulation with MRSA for 4 hours. Data are shown as mean ± SEM; n = 3-6.

[0031] Figure 5The figure shows the protective effect of Esculin on MRSA-induced ALI in mice, where A: experimental design of ALI model and pretreatment regimen of Esculin; B: representative H&E staining of lungs of control group and ALI mice and images of MRSA bacterial load in culture dishes (scale bar: 100 µm, magnification: ×200); C: Kaplan-Meier survival curve of mice in each group; D: ELISA results of IL-1β and TNF-α cytokine expression in lungs; E: histological score of lungs; F: quantitative results of bacterial load in lungs; G: wet / dry weight ratio of lungs; H: protein concentration in BALF; I: neutrophils in BALF; J: macrophages in BALF; K: MDA level in lungs; L: SOD level in lungs; M: GSH level in lungs; N: T-AOC level in lungs; O: western blot analysis of lung tissues IL-1β, IL-8 and TNF-α levels detected by blot; P: quantification of CD86 and CD206 expression by flow cytometry; Q: ratio of CD86; R: ratio of CD206. Data in the figure are shown as mean ± SEM; n = 3-10.

[0032] Figure 6 The figure shows that Esculin increases M2 polarization and alleviates MRSA-induced inflammation by inhibiting the TLR2-MyD88-NFκB signaling pathway, reducing the level of Keap1 and activating the Nrf2 / ARE signaling pathway, wherein A: western blot analysis of the expression of Keap1, Nrf2, NQO1 and HO-1; B: western blot analysis of the expression of TLR2, MyD88, p-p65, p65, TNF-α, IL-6, IL-1β; C: statistical analysis of the expression of TLR2, MyD88, TNF-α, IL-6, IL-1β; D: statistical analysis of the expression of p-p65 and p65; E: statistical analysis of the expression of Keap1, Nrf2, NQO1 and HO-1; F: interaction PPI network analysis of M1 and M2 related proteins; G: overall summary of the molecular docking and binding sites of Esculin and Keap1; H: overall summary of the molecular docking and binding sites of Esculin and TLR2. The data in the figure are shown as mean ± SEM; n = 3. DETAILED DESCRIPTION

[0033] The present application is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or according to the conditions recommended by the manufacturer.

[0034] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. The reagents or raw materials used in this application can be purchased through conventional channels. Unless otherwise specified, the reagents or raw materials used in this application are used in a conventional manner in the art or in accordance with the product instructions. In addition, any method and material similar to or equivalent to the content described herein can be applied to the method of this application. The preferred implementation methods and materials described in the text are for demonstration purposes only.

[0035] Example

[0036] 1. Materials and Methods

[0037] 1.1 Materials

[0038] iNOS, Arg1, Nrf2, Keap1, HO-1, TLR2, MyD88, IL-6, IL-1β, and TNF-α antibodies were purchased from Affinity Biosciences (Ohio, USA), and p65 and p-p65 antibodies were purchased from Abcam (Massachusetts, USA). IL-6, IL-1β, and TNF-α ELISA kits were purchased from Animalunion Biotechnology Co., Ltd. (Shanghai, China). Lactate dehydrogenase (LDH), nitric oxide (NO), malondialdehyde (MDA), glutathione (GSH), total antioxidant capacity (T-AOC), and superoxide dismutase (SOD) assay kits were purchased from Beijing Box Biotechnology Co., Ltd. (Beijing, China). Esculin was purchased from MedChemExpress (HY-N0188, ≥ 99.78% HPLC, Shanghai, China).

[0039] 1.2 Cell culture and bacterial strains

[0040] RAW264.7 cells (TIB-71TM, ATCC) were grown in DMEM medium containing 1% penicillin-streptomycin and 10% fetal bovine serum at 37°C in 5% CO 2 BSSK14 (B. safensis, CCTCC M 20241071) and other strains were isolated from Northeastern pickled cabbage.

[0041] Prior to the experiment, the number of viable MRSA colonies and other strains was determined using the plate count method. These strains were sequentially passaged for a minimum of three generations using a 1% (v / v) inoculum. The cultures were transferred to fresh medium between each passage. The cultures were centrifuged at 12,000 × g for 2 min at 4°C and then washed three times with PBS, pH 7.0.

[0042] 1.3 Screening of strains with anti-inflammatory activity

[0043] RAW 264.7 cells (1.0 × 10 5 cells / mL) were seeded in 24-well cell culture plates and incubated at 37°C with 5% CO 2 The cells were then incubated overnight at 4 °C. Subsequently, the RAW 264.7 cells were washed twice with PBS and 1 ml of fresh DMEM without antibiotics was added to each well. The monolayers were then inoculated with bacterial isolates (1.0 × 10 8 CFU / mL) for 16 hours. After treatment, the cells were divided into two groups. One group was added with MRSA (1.0 × 10 7 CFU / mL) for 4 hours, and the other group was not stimulated with MRSA. After stimulation, the culture supernatant was collected and the NO level was quantified using a NO content assay kit. The results were expressed as the percentage of NO production and calculated as (test / positive control) × 100.

[0044] 1.4 Animal Model

[0045] BALB / c mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. and housed in an SPF clean animal facility, where environmental parameters were maintained at 22–24°C, 12-h light / dark cycle, 40–70% humidity, and 15 times / h ventilation. Methods for establishing the MRSA-induced ALI mouse model: Mice were anesthetized by intraperitoneal injection of ulexol (Solarbio, Beijing, China). Subsequently, MRSA suspension (1 × 10 8 In the live BS SK14 and BS SK14 supernatant prevention experiments, mice were given the indicated amount of live BS SK14 (1 × 10 9 / mouse) or live BSSK14 supernatant (200 µL). Correspondingly, the control group was orally gavaged with dead BS SK14 cells (at a dose of 1 × 10 9 per mouse) or 200 µL blank medium. In the esculin treatment experiments, mice were given 30 mg / kg esculin dissolved in saline and sonicated by oral gavage 14 days before MRSA infection. Each group contained 10 mice. All mice were monitored for survival within 72 hours after MRSA infection and then CO 2 Mice were killed by gas injection and blood was collected after the mice ceased to have pedal reflex.

[0046] Safety evaluation of BS SK14 in mice: Ten mice were randomly divided into two groups: BS SK14 group (5 mice) and PBS group (5 mice). Each group was given BS SK14 (1×10 10 CFU / mouse) or PBS for 14 days. During the experiment, the mice were continuously evaluated for clinical manifestations, weight changes, signs of toxicity, and mortality.

[0047] 1.5 Bronchoalveolar lavage fluid and tissue collection

[0048] Bronchoalveolar lavage fluid (BALF) was obtained by lung lavage with 2 mL of 3 mmol / L EDTA in PBS and divided into two 1 mL aliquots. The protein concentration in BALF was determined using the Bradford protein concentration assay kit (Beyotime, Shanghai, China). The cellular components of BALF were analyzed by cell counting and staining with Quick-Diff solution (Solarbio, Beijing, China). After opening the chest cavity of the mice, 10 mL of cold PBS was injected through the right ventricle to eliminate blood residues. Afterwards, the left lung lobe was used for flow cytometric analysis and tissue sectioning, while the right lung lobe was collected and kept in an ice-cold state until homogenization and then stored at -80°C to evaluate cytokine levels and lung tissue integrity.

[0049] 1.6 Bacterial count

[0050] The lungs were removed aseptically and homogenized using a tissue grinder. The homogenate was serially diluted tenfold with PBS to 10 5 Subsequently, 100 μL of the tissue suspension was plated on Baird-Parker agar medium (OXOID, Hampshire, UK) and incubated at 37°C for 24 h. The bacterial colonies in each lung were counted and the CFU were calculated.

[0051] 1.7 Flow cytometry and cell sorting

[0052] Preparation of single-cell suspensions of mouse lungs: Lungs were extracted and the main airways were separated from the surrounding tissue. Subsequently, the latter were cut into smaller fragments with scissors and transferred to 2.0 EP tubes. These fragments were treated in digestion buffer (Roche, Indianapolis, IN) containing collagenase IV (1 mg / mL) and DNase I (0.1 mg / mL) and then digested at 37°C for 30 min. The homogenized lungs were filtered through a 70 µm nylon mesh to obtain a single-cell suspension. Residual erythrocytes were lysed using BD PharmLyse (BD Biosciences, San Jose, CA), and the resulting cell population was quantified.

[0053] The collected cells were resuspended in 100 μL cold PBS, and cell debris and dead cells were removed using the Zombie NIR™ Fixable Viability Kit (Biolegend). Subsequently, Fc receptors were blocked with anti-mouse CD16 / CD32 antibodies (BD Biosciences), and then stained with anti-mouse CD45 (FITC, BD Biosciences), anti-mouse F4 / 80 (APC, BD Biosciences), anti-mouse CD11c (PE, BD Biosciences), anti-mouse CD86 (BV650, BD Biosciences), and anti-mouse CD206 (BV421, BD Biosciences) antibodies at 4°C for 30 minutes in the dark. After staining, all cells were washed three times with cold PBS to remove unbound antibodies, suspended in 300 μl PBS, and analyzed using LSR FortessaTM (BD Biosciences). Isotype control antibodies were used as negative controls. Data analysis was then performed using Flow Jo software (version 7.6.1, Tree Star Inc., USA).

[0054] 1.8 Western blotting and protein-protein interaction (PPI) analysis

[0055] Western blot analysis: Protein band quantification was performed using the Amersham Imager 680 system. Protein-protein interaction (PPI) network analysis was performed using the STRING database (http: / / string-db.org / , version 12.0).

[0056] 1.9 Molecular docking analysis

[0057] The two-dimensional structures of small molecule ligands were obtained from PubChem database (http: / / pubchem.ncbi.nlm.nih.gov / ) and converted into three-dimensional structures using ChemOffice 20.0 software and saved as mol2 files. The high-resolution crystal structure of the protein target was selected from RCSB PDB (http: / / www.rcsb.org / ) for molecular docking. The protein structure was desolvated and dephosphorylated using PyMOL2.6.0 software and saved as PDB files. Ligand energy minimization was performed using Molecular Operating Environment (MOE) 2019 software, while the target protein was pre-processed to identify the active pocket. Molecular docking was performed using MOE 2019 software. The evaluation of ligand binding affinity was based on the binding energy value, and the results were visualized using PyMOL 2.6.0 and Discovery Studio 2019 software.

[0058] 1.10 Statistical analysis

[0059] Statistical analyses were performed using GraphPad 10, SPSS 27.0, R-4.4.0, and ImageJ 1.54i. The normality of data distribution was assessed by the Kolmogorov–Smirnov test, and significant differences were determined using ANOVA followed by Tukey's HSD test. Statistical significance was defined as p < 0.05, and p values ​​were not corrected for multiple testing unless explicitly stated. Data are presented as mean ± standard error of the mean (SEM).

[0060] 2. Results

[0061] 2.1 Anti-inflammatory and safety profile of BS SK14

[0062] Twenty-seven potential probiotic strains were isolated from sauerkraut. To evaluate their anti-inflammatory effects against MRSA infection, an in vitro evaluation was performed using the RAW 264.7 cell line, focusing on MRSA-induced NO production (see Figure 1 , A). The strains were observed to have different anti-inflammatory properties, with NO levels ranging from 6% to 95%. One strain performed particularly well and was identified as Bacillus saffron and was named Bacillus saffron ( Bacillus safensis )SK14 (abbreviated as BSSK14), whose 16S ribosomal RNA (16S rRNA) gene sequence is shown in SEQ ID NO: 1.

[0063] In particular, BS SK14 significantly reduced NO production in MRSA-stimulated RAW 264.7 cells to less than 10%, demonstrating its high anti-inflammatory potential. In addition, the NO levels of control macrophages not infected with MRSA did not change significantly after pretreatment with BS SK14 (see Figure 1 , B).

[0064] In addition, the levels of inflammatory cytokines (TNF-α, IL-6, and IL-1β) were significantly reduced in macrophages challenged with MRSA (see Figure 1 , C) (P < 0.001). A 14-day oral treatment regimen using a dose ten times higher than the standard dose (1 × 10 10 CFU / mouse), the safety of BS SK14 was evaluated. No obvious signs of toxicity or lethality were observed in any experimental animal group throughout the scientific analysis. In addition, there was no significant deviation in the average body weight of animals in the BS SK14 group and the PBS group during the two-week observation period (see Figure 1 , D).

[0065] In further serum biochemical analysis, there were no significant differences in alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine (CK), or blood urea nitrogen (BUN) concentrations between the BS SK14 group and the PBS group (see Figure 1 , E to I). Similarly, the levels of serum inflammatory cytokines (TNF-α, IL-6, or IL-1β) remained unchanged without significant changes (see Figure 1 , J to L). Histopathological examination of key organs (including heart, liver, lungs, kidneys, or spleen) revealed no significant abnormalities (see Figure 1 , M). These results emphasize the safety and non-toxicity of BS SK14.

[0066] 2.2 Protective effect of live BS SK14 on MRSA-induced acute lung injury in mice

[0067] Before MRSA vaccination (see Figure 2 , A) Mice were pretreated with PBS, live BS SK14, or heat-neutralized BS SK14 to evaluate the in vivo protective effect of BS SK14 against MRSA-induced acute lung injury (ALI). Significantly, the survival rate of mice pretreated with live BS SK14 was significantly higher than that of the control group pretreated with PBS or dead BS SK14 (P < 0.05, see Figure 2, C). Detailed evaluation of lung pathology showed that the ALI group exhibited severe inflammation compared with the control group. However, pretreatment with live BS SK14 reduced the alveolar wall thickening and massive infiltration of inflammatory cells caused by MRSA infection (see Figure 2 , B, and D), and reduced the levels of proinflammatory cytokines such as IL-6, IL-1β, and TNF-α.

[0068] In addition, the experiment also evaluated the effect of BS SK14 on other key indicators of ALI in mice. A significant increase in lung wet / dry weight ratio was observed after MRSA challenge, while a significant decrease was observed after pretreatment with live BS SK14 (P < 0.01, see Figure 2 , F). In addition to the BALF protein concentration (P < 0.05, see Figure 2 , G), the number of neutrophils and macrophages, the inflammatory markers caused by ALI, was significantly reduced after pretreatment with live BS SK14 in ALI model mice (P < 0.05, see Figure 2 , J and K). The bacterial load of MRSA was also significantly reduced (P < 0.001, see Figure 2 , H and I), highlighting its efficacy in bacterial elimination. In addition, ALI caused severe oxidative stress damage to the lungs. As expected, BS SK14 significantly reduced MDA levels (P < 0.05, see Figure 2 , L), and increased the levels of antioxidants, such as SOD (P < 0.05), GSH (P < 0.01), and T-AOC (P < 0.01, see Figure 2 , M to O). Collectively, these findings indicate that only live BS SK14 can significantly attenuate these inflammatory markers in ALI model mice.

[0069] 2.3 Effects of BS SK14 culture supernatant on ALI model mice

[0070] In this experiment, we analyzed whether the culture supernatant of live BS SK14 could alleviate the adverse effects of ALI (see Figure 3 , A). The number of deaths in ALI model mice treated with BS SK14 supernatant was reduced (P < 0.001, see Figure 3 , C). Pathological analysis of lung tissue showed that inflammatory cell infiltration was reduced and alveolar structural damage was alleviated (P<0.001, see Figure 3 , B and D), while the lung inflammatory cytokines IL-6 (P < 0.05), IL-1β (P < 0.001) and TNF-α (P < 0.01, see Figure 3 , E) expression was also reduced.

[0071] In addition, the lung wet / dry weight ratio was significantly decreased (P < 0.001, see Figure 3 , F), the number of neutrophils and macrophages decreased (P<0.05, P<0.001, see Figure 3 , J and K), and the BALF protein concentration also decreased (P < 0.01, see Figure 3 , G). The live BSSK14 culture supernatant showed significant bactericidal activity, and the MRSA count in the lungs was significantly reduced (P < 0.001, see Figure 3 , H and I). In addition, the culture supernatant of BS SK14 effectively reduced the increase of MDA level (P < 0.01, see Figure 3 , L), and increased SOD (P<0.01), GSH (P<0.05) and T-AOC (P<0.05, see Figure 3 , M to O) levels in ALI model mice. These effects were specific to the BS SK14 supernatant group and were not observed in the blank supernatant group. Overall, the above results indicate that the live strain supernatant significantly improved the survival rate of ALI model mice, which may be due to the protective metabolites produced by BS SK14.

[0072] 2.4 Esculin produced by BS SK14 reduces MRSA-induced inflammation via M2 polarization in RAW 264.7 cells

[0073] The culture supernatants of the NB Blank and Live supernatant BS SK14 groups were analyzed by LC‒MS / MS analysis to identify the bacterial protective substances responsible for the anti-inflammatory effect of BS SK14 (see Figure 4 , A). Principal component analysis (PCA) showed clear differences in metabolic profiles between the two groups (see Figure 4 , B). Enrichment analysis of these metabolic differences revealed that 39 metabolites were significantly increased in the supernatant of BS SK14 (see Figure 4 , D), among which aesculin showed the greatest change and was used for further study (see Figure 4 , E). Next, the anti-inflammatory effect of esculin was tested using RAW 264.7 cells. LDH release is often used as an indicator of cell damage. The maximum concentration of esculin (150 µM) had no significant cytotoxic effect on cells (P>0.05, see Figure 4 , F). It is noteworthy that with the application of esculin, the cell damage caused by MRSA was significantly reduced in a dose-dependent manner (P<0.05, see Figure 4 , as shown in G).

[0074] Considering that aesculin plays a central role in the anti-inflammatory and antibacterial activities of BS SK14, the levels of pro-inflammatory cytokines in MRSA-infected cells were analyzed. When the concentration reached 120 μM, the relative expression levels of IL-6, IL-1β, and TNF-α were significantly reduced and did not change with increasing doses (P<0.05, see Figure 4 , H). In addition, the ELISA results showed a significant effect, indicating that 120 μM was the optimal concentration of aesculin in this experiment (P < 0.001, see Figure 4 , J).

[0075] In addition, flow cytometry was used in the experiment to detect the changes in macrophage polarization after aesculin treatment, and the results showed a similar trend. Macrophages can regulate inflammatory responses by polarizing into M1 and M2 phenotypes. M1 polarization involves the secretion of a large number of pro-inflammatory mediators, while M2 polarization involves the secretion of anti-inflammatory factors that promote healing. Flow cytometry results showed that aesculin pretreatment reduced the expression of M1 phenotype markers (CD86) and increased the expression of M2 phenotype markers (CD206) (see Figure 4 ,I), indicating that esculin inhibited MRSA-induced M1 macrophage polarization and promoted M2 macrophage polarization.

[0076] Finally, esculin reduced the level of MDA (P < 0.05, see Figure 4 , K) and increased T-AOC (P<0.05), SOD (P<0.01) and GSH (P<0.05, see Figure 4 , L to N) levels, showing significant antioxidant activity, thereby alleviating oxidative stress damage in cells. The above results indicate that BS SK14 protects RAW264.7 cells from MRSA infection through its small molecule metabolite aesculin. This protection may be through aesculin inhibiting MRSA-induced M1 macrophage polarization and promoting M2 macrophage polarization, leading to other anti-inflammatory and antioxidant effects.

[0077] 2.5 Protective effect of esculin on ALI in BALB / c mice induced by MRSA

[0078] To investigate the therapeutic potential of esculin, mice were pretreated with 30 mg / kg esculin before MRSA challenge (see Figure 5 , A). Esculin significantly improved the survival of ALI model mice, as shown by a prolonged survival curve compared with the control group (P<0.001, see Figure 5 , C). Histopathological evaluation further confirmed the therapeutic effect of aesculin, with a significant reduction in pulmonary congestion, interstitial edema, and alveolar wall thickness, leading to a significant reduction in inflammatory cell infiltration (P < 0.001, see Figure 5 , B and E).

[0079] The determination of pro-inflammatory cytokine levels in the lungs of mice further confirmed the anti-inflammatory ability of aesculin, with IL-6, IL-1β, and TNF-α levels significantly reduced (P < 0.001, see Figure 5 , D). In addition, the lung wet / dry weight ratio was significantly reduced (P < 0.001, see Figure 5 , G), indicating that aesculin reduced pulmonary edema. Neutrophil and macrophage detection showed that inflammatory cell infiltration was reduced (P < 0.01, P < 0.05; see Figure 5 , I and J ) and decreased with the decrease in BALF protein concentration ( P < 0.001; see Figure 5 , H), indicating that the inflammatory response was partially improved. In addition, esculin increased bacterial clearance and significantly reduced MRSA colonization in the lungs (P < 0.001, see Figure 5 , F).

[0080] To better understand how esculin enhances the antioxidant capacity of mice, serum levels of relevant oxidative stress markers were measured. MDA levels were significantly reduced (P < 0.001, see Figure 5 , K), while T-AOC (P<0.01), SOD (P<0.01) and GSH (P<0.05, see Figure 5 , L to M) levels were significantly increased. In addition, flow cytometry revealed that MRSA may promote the polarization of mouse M1 macrophages, enhance their pro-inflammatory function, and aggravate the inflammatory response. However, aesculin inhibited this effect. Flow cytometry results showed that the expression of CD206 was significantly increased, while the expression of CD86 was significantly decreased (P<0.001, see Figure 5 , O to Q), promoted the polarization of M2 macrophages. Western blot analysis further confirmed the effect of esculin and showed a decrease in the expression level of M1 marker iNOS (P < 0.05) and an increase in the expression level of M2 marker ARG1 (P < 0.01, see Figure 5 , N), indicating that esculin has anti-inflammatory effects and tissue repair ability in ALI model mice.

[0081] 2.6 Esculin promotes macrophage M2 polarization via Keap1 / Nrf2 / ARE and TLR2-MyD88-NFκB pathways

[0082] There is a connection between macrophage polarization and Toll-like receptors (TLRs), and the mechanism of esculin-induced M2 macrophage polarization and its anti-inflammatory and antioxidant effects was elucidated in this example. TLR2 is a receptor for Gram-positive bacteria, and NF-κB is a key mediator of inflammatory responses triggered by TLRs in macrophages. These two factors play a key role in promoting M1 macrophage polarization, and excessive M1 polarization may lead to inflammation and tissue damage.

[0083] The experimental results showed that the levels of TLR2, MyD88, and phosphorylated NF-κB p65 were significantly increased in the MRSA group. However, esculin treatment led to a decrease in the expression of these proteins in the lung tissues of MRSA-induced ALI model mice. The reduction in the M1 macrophage population was accompanied by a decrease in the levels of proinflammatory cytokines, including IL-6 (P<0.05), IL-1β (P<0.01), and TNF-α (P<0.001, see Figure 6 , B and C). Molecular docking analysis showed that esculin could enter the binding domain of TLR2 target protein, and its docking energy was -6.1620 kcal / mol. Residues Asp160, Thr161, Gly133 and Asp182 on the TLR2 receptor formed hydrogen bond interactions with esculin, while residue Gly133 also formed hydrophobic interactions. In addition, the Tyr109 residue on the receptor formed a Pi-Pi interaction with esculin, while the Met159 residue formed a Pi-Sulfur interaction, indicating that there was a favorable binding between esculin and TLR2 (see Figure 6 , G). The experimental results showed that aesculin may inhibit M1 macrophage polarization by inhibiting MRSA infection-induced TLR2 upregulation and NF-κB p65 phosphorylation.

[0084] In addition, esculin also alleviated the oxidative stress caused by ALI. The Keap1 / Nrf2 / ARE pathway is a central anti-oxidative stress defense mechanism, and proteins such as HO-1 and NQO1 play a key role in promoting M2 macrophage polarization. Therefore, the effect of esculin on the expression of proteins involved in the Keap1 / Nrf2 / ARE pathway was examined in the experiment (see Figure 6 A). Compared with the control group, the expression of Keap1 was significantly increased, and the expressions of NRF2, NQO1, and HO-1 were significantly decreased in the MRSA group. However, pretreatment with esculin significantly decreased the expression of Keap1 (P<0.05) and increased the expression of NRF2 (P<0.01), NQO1 (P<0.001), and HO-1 (P<0.05) (see Figure 6, A and E). Molecular docking results showed strong interactions between esculin and Keap1 receptor residues, including Val418, Val465, Ile559, and Gly367 bound by hydrogen bonds and hydrophobic interactions, and Ala366 bound to esculin by hydrophobic interactions. The docking energy was calculated to be -7.2132 kcal / mol, indicating that it has strong binding activity (see Figure 6 , H). This finding suggests that esculin may alleviate oxidative stress and promote M2 macrophage polarization by interfering with Keap1 / Nrf2 interaction and activating Nrf2 signaling.

[0085] The interaction network of M1 and M2 proteins (see Figure 6 , F), clarified the relationship between proteins in the TLR2-MyD88-NFκB and Keap1 / Nrf2 / ARE pathways, and revealed the protective mechanism of aesculin in ALI caused by MRSA

[0086] 3. Discussion

[0087] In the present application, it was found that BS SK14 played a key role in reducing MRSA-induced inflammation by producing esculin, thereby maintaining pulmonary immune homeostasis. The results of the present application have demonstrated that the administration of esculin promoted macrophage M2 polarization and enhanced resistance to MRSA. In addition, esculin played an antioxidant role by inhibiting the TLR2-MyD88-NF-κB pathway, reducing Keap1 levels, and activating the NRF2 / ARE pathway, improving MRSA-induced ALI.

[0088] In this application, a large number of bacterial strains were isolated from Northeast China sauerkraut, and it was found that BS SK14 could reduce the levels of MRSA-induced inflammatory factors in RAW264.7 cells (see Figure 1 ).

[0089] MRSA is a highly drug-resistant pathogen that can cause a variety of serious infections, including lung infections that may lead to ALI. Based on in vivo and in vitro experiments and LC-MS / MS analysis, the present application reveals that aesculin, a metabolite produced by living BSSK14, has a significant protective effect against MRSA infection in RAW264.7 cells and ALI model mice. Aesculin has been reported to have various biological functions, including increasing intestinal antioxidant activity, reducing cardiac inflammation and apoptosis. In addition, aesculin has direct antibacterial activity against pathogens such as Staphylococcus aureus, Enterococcus faecalis and Escherichia coli. This antibacterial property of aesculin contributes to the observed protective effect of BS SK14, which relieves inflammation by reducing the bacterial load of MRSA colonizing the lungs. Although coumarins can be synthesized from various plants, the use of microbial synthesis may provide an alternative method. The natural probiotic BS SK14 provided in the present application may be more suitable for the production of aesculin based on its probiotic effect and is a safer and more efficient source for the production of aesculin.

[0090] Scientific studies have confirmed that MRSA, a Gram-positive bacterium, can trigger an inflammatory response through the NF-κB signaling pathway activated by TLR2. Activation of this pathway triggers M1 macrophage polarization, thereby exacerbating inflammation. Conversely, blocking the TLR2-mediated NF-κB pathway can reduce M1 macrophage activation and inflammation. In addition, due to the drug resistance of MRSA, the treatment of MRSA-induced ALI is particularly challenging and requires specific antibiotics and comprehensive treatment. Therefore, it is crucial to find safer and more effective alternatives.

[0091] In the present application, it was found that esculin was able to inhibit the NF-κB pathway and the expression of inflammatory factors caused by Gram-positive bacteria, while promoting the transformation of M1 macrophages to M2 type in RAW264.7 cells and MRSA-induced ALI model mice. In addition, the use of esculin led to a decrease in TLR2 protein concentration in the MRSA-induced ALI mouse model. Molecular docking analysis further confirmed the stable binding interaction between esculin and TLR2, indicating that esculin is a potential TLR2 inhibitor for the treatment of inflammatory diseases caused by Gram-positive bacteria. KEAP1 and NRF2 also play a role in inflammation mediated by Gram-positive bacteria. The activation of NRF2 increases the production of enzymes such as HO-1 and NQO1, counteracts oxidative stress and regulates the balance of M1 / M2 macrophages. Normally, NRF2 binds to KEAP1 in the cytoplasm and regulates its expression. When stimulated by external factors, NRF2 separates from KEAP1 and migrates to the nucleus, acting as a transcription factor. The study in this application confirmed that by targeting KEAP1, esculin upregulated the expression of NRF2, HO-1, and NQO1, promoted M2 macrophage polarization, and reduced MRSA-induced inflammatory factors and oxidative stress. The ability of esculin to reduce MDA levels and increase GSH, T-AOC, and SOD levels further emphasizes its antioxidant capacity in the case of ALI.

[0092] 4. Conclusion

[0093] In summary, this application illustrates the therapeutic effect of live BS SK14 on MRSA-induced ALI and explores its production of esculin. The study of this application showed that esculin significantly inhibited the TLR2-MyD88-NFκB pathway, reduced Keap1 levels, and activated the NRF2 / ARE signaling pathway. These molecular events led to a significant decrease in M1 macrophage polarization and an increase in M2 macrophage polarization in MRSA-induced ALI model mice. Therefore, this intervention significantly alleviated MRSA-induced ALI in the mouse model.

[0094] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. Although the present application is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. A strain of Bacillus sabogensis, which is named Bacillus sabogensis ( Bacillus safensis ) SK14, the strain was deposited in the China Center for Type Culture Collection, Wuhan University, Wuhan, China on May 27, 2024, with the deposit number CCTCC NO: M 20241071.

2. A composition comprising the Bacillus safonisi described in claim 1.

3. Use of the Bacillus safovici according to claim 1 or the composition according to claim 2 in the preparation of a medicament for preventing and / or treating acute lung injury caused by methicillin-resistant Staphylococcus aureus.

4. Use of the Bacillus sabdariffa according to claim 1 or the composition according to claim 2 in the preparation of a medicament having anti-inflammatory and / or antioxidant effects.

5. Use of the Bacillus sabdariffa according to claim 1 or the composition according to claim 2 in the preparation of antibacterial drugs or anti-infective drugs, wherein: The antibacterial agent refers to anti-methicillin-resistant Staphylococcus aureus, and the anti-infection agent refers to infection caused by anti-methicillin-resistant Staphylococcus aureus.

6. A method for producing aesculin, characterized in that: include: Cultivate the Bacillus sabdariffa described in claim 1, and obtain aesculin from its fermentation broth.